Piramal Pharma Q1 Results Review - Work In Progress To Revive Business Across Segments: Motilal Oswal

Motilal Oswal Report

Piramal Pharma Ltd. posted a better-than-expected performance in Q1 FY24. It witnessed a strong uptick in the order book for its contract development and manufacturing organisation business, supported by sustained volume growth in Sevoflurane in the complex hospital generics segment.

Although Piramal Pharma reported a net loss of Rs 986 million in Q1 FY24, we believe that with the revival in business and debt reduction, it will return to profitability.

We raise our FY24/FY25 estimates by 1%/3%, factoring in better growth prospects in the CDMO/CHG segments and a reduction in interest costs.

We value Piramal Pharma on an SOTP basis (11 times enterprise value/Ebitda of CDMO business, 11 times EV/Ebitda forcomplex hospital generics, and 12 times India consumer products) to arrive at a target price of Rs 125.

Piramal Pharma remains on track to improve its earnings outlook and return ratios through-

1. increased visibility for innovation-related work and active pharma ingredient business in the CDMO segment, and

2. incremental launches and market share gains in existing products in the complex hospital generics/India consumer products segment.

We reiterate our 'Buy' rating on the stock.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.